Multiple Sclerosis Resource Centre
  • Home
  • MSRC Grand Opening 30/05/12
  • About MS
  • MSRC Services
  • Get Involved
  • MS Research News
  • MSRC Groups
  • Useful Resources
  • Welcome To Josephs Court, MS Centre Of Excellence
  • Advertising
  • Best Bet Diet Group
  • E-Newsletter
  • Contact Us
  • Investor in People
    You are here : Home » MS Research News » New Discoveries » Uric Acid

    Uric Acid

    A A A
    [Print this page]

    Share |

    Serum Uric Acid With Multiple Sclerosis And Other Neurological Diseases
    The serum uric acid (UA) levels were measured in 112 patients with multiple sclerosis (MS) and 794 patients with different types of other neurological diseases (OND) or healthy control group. Serum UA levels, along with relevant clinical parameters of MS and OND, were also investigated.

    MS patients had significantly lower UA levels than those with

    • Transient ischemia attack (344.6+/-130.6 micromol/L, P=0.000)
    • Cerebral hemorrhage (311.9+/-104.7 micromol/L, P=0.000)
    • Cerebral infarction (291.3+/-101.6 micromol/L, P=0.014)
    • Healthy control group (312.1+/-92.8 micromol/L, P=0.000)

    MS patients had significantly higher serum UA levels than those with:

    • Cryptococcus meningitis or meningoencephalitis (178.9+/-107.0 micromol/L, P=0.000)
    • Tuberculous meningitis or meningoencephalitis patients (175.7+/-99.9 micromol/L, P=0.000)

    There were no significant differences in UA levels between patients with MS and those with:

    • Facial neuritis
    • Viral meningitis or encephalitis
    • Pulmonary tuberculosis Polymyositis or dermatomyositis
    • Myasthenia gravis
    • Subarachnoid hemorrhage
    • Migraine
    • Guillain-Barre syndrome
    • Myelitis

    In addition, uric acid levels were independently correlated with gender and duration of MS, but neither with MRI activity, disability nor subtypes of the disease in MS patients. Our data suggest that UA has two biphasic functions: neuroprotective and injurious. Our studies may help physicians to deal with conditions having abnormal UA levels.

    Peng F, Zhang B, Zhong X, Li J, Xu G, Hu X, Qiu W, Pei Z.

    Department of Neurology, The Third Affiliated Hospital of Sun Yat-Sen University, 600 Tianhe Road, Guangzhou 510630, Guangdong Province, People’s Republic of China.

    Multiple Sclerosis October 2007 (19/10/07)

    Uric acid and spinal cord injury treatment
    A novel approach from Rutgers holds potential for central nervous system damage.

    Uric acid is commonly associated with the excruciatingly painful joint disease known as gout, but it can also play a crucial role in the treatment of spinal cord injury and other central nervous system disorders, such as stroke, multiple sclerosis and Parkinson's disease, according to Rutgers' Bonnie Firestein.

    Firestein, an associate professor of cell biology and neuroscience at Rutgers, The State University of New Jersey, and her laboratory team have reported their discovery in the Early View (online in advance of print) version of the journal Glia.

    "In spinal cord injury, as well as stroke, two kinds of damage can occur," Firestein explained. "First there is the physical damage, but this is followed by secondary chemical damage to neurons [nerve cells] by compounds released in response to the trauma. We have found that uric acid can promote an early intervention step in combating this chemical damage through its action on astroglial cells."

    Astroglial cells or astrocytes are specialised cells that support neuron function with nutrients and protective buffering.

    In addition to the scientific achievement, the research study is a model for student involvement and education. Among the co-authors, postdoctoral associate Yangzhou Du is teaching Firestein more about astroglial cells, while he is learning about neurons from her. Christopher Chen was a Henry Rutgers Honors undergraduate student on the study, and Yuval Eisenberg, a laboratory technician; both now attend medical school. Another student, Chia-Yi Tseng is continuing her graduate studies in Firestein's laboratory.

    Uric acid's effects on the health of neurons had been observed by other researchers, but the mechanics of how it confers protection has remained a mystery.

    "It is interesting to note that people with gout never seem to develop multiple sclerosis," Firestein said. "In animal models of multiple sclerosis, the addition of uric acid reduces symptoms and improves prognosis. The same is true for one type of Parkinson's disease tested."

    The Firestein team's breakthrough studies revealed that uric acid can stimulate astroglial cells to produce transporter proteins that carry harmful compounds away from neurons in jeopardy of chemical damage. This opens the door to identifying a unique drug target for new therapies.

    Glutamate is a compound that under normal circumstances aids neurons in transmitting signals for cognitive functions in the brain, such as learning and memory. In the case of spinal cord injury or stroke where there is physical cell damage, however, an excess of glutamate is released and it accumulates around the remaining intact neurons, eventually choking them to death.

    When Firestein's group added uric acid to a mixed culture of rat spinal cord neurons and astroglial cells, the production of the glutamate transporter EAAT-1 increased markedly. The challenge now is find the most effective strategy for increasing the production of the transporter, using drug therapies or other means.

    Firestein said that a collaborative team of colleagues from Baylor College of Medicine and the University of Rochester Medical Center has devised one such strategy. With this team, Firestein will develop a line of stem cells that has been modified to generate astrocytes that produce large quantities of the EAAT-1 transporter. Adding these to an injury site, either alone or in combination with uric acid, holds great potential, she said.

    The study was supported by a grant from the New Jersey Commission on Spinal Cord Research.

    070103-1 Firestein Uric Acid (03/01/07)

    © Multiple Sclerosis Resource Centre

    Related Items
    Abnormal Liver Tests and MS
    Aluminium and Multiple Sclerosis
    Antagonist compounds
    Antibodies, B Cells,T-Cell Activation, Immune Response
    Apolipoprotein D
    Bacteria & MS
    Biomarkers and MicroRNA
    Blood tests
    Bone Marrow Cells and MS Treatment
    Bowmann-Birk Inhibitor Concentrate (BBIC)
    Brain Atrophy, Lesion Loads, White and Grey Matter
    Brain Inflammation
    Brain Iron Deposits
    Calcium Binding Proteins
    Cerebro-Spinal Fluid & Spinal Cord
    Chronic Cerebrospinal Venous Insufficiency (CCSVI)
    CXCL1, 7, 12
    Cytokines & Chemokines
    Dendritic Cells
    Estrogen Receptors
    Fibrinogen, Mac-1 and Microglia
    Histamine and MS
    Hormones And MS Research
    Infections and Multiple Sclerosis Relapses
    JAK-STAT inhibitors
    Kallikrein 6
    Lipids & MS
    Medical Imaging
    Mycoplasmas And Bacteria
    N-acetylglucosamine (GlcNAc) & Glucosamine
    Natural Interferon Beta
    Natural Killer Cells
    Nerve and Brain Cell Research
    Olig 1 Gene Discovery
    Oligodendrocytes and Astrocytes
    Pesticides and Multiple Sclerosis
    Plasma Exchange
    Potential Viral Causes of MS
    Recombinant Human Erythropoietin
    Regeneration Research
    RNA and RNAi
    Synthetic Small Molecules
    Tetanus Vaccine and Possible MS Protection
    The Blood Brain Barrier
    Tremors And MS
    Urinary Problems
    Vascular Function And MS
    Vision and MS

    Did you find this information useful? Would you like to comment on this page? Let us know what you think! We welcome all comments and feedback on any aspect of our website - please click here to contact us.